Psychopharmacology for the Clinician
The information in this column is not intended as a definitive treatment strategy but as a suggested approach for clinicians treating patientswith similar histories. Individual cases may vary and should be evaluated carefully before treatment is provided. The patient described in thiscolumn is a composite with characteristics of several real patients.
Off-label antipsychotic use and tardive
dyskinesia in at-risk popu lations: new
drugs with old side effects
over the years, with limited response.
anxiety, led to an antipsychotic trial.
in off-label antipsychotic use across all
age groups,1–5 perhaps reflecting their
reputation. In addition, the field is sanc-
fect. In the second year of treatment, he
were initially attributed to on going den-
with the atypical antipsychotics,9–11 all
tients, 2 populations particularly sensi-
part of our clinical decision-making.
Gary Remington, MD, PhD
Margaret Hahn, MD, PhD
abuse, race, sex and genetics.11–15 There
Centre for Addiction and Mental Health
and to schizophrenia itself.16–19 Studies
Both authors declare
also declares consulting fees from Roche,
chroneron and grants from Neurocrine andMedicure.
ments (i.e., localized, perioral). Within
Psychopharmacology for the Clinician columns are usually based on a case report that illustrates a point of interest in clinical psychopharma-cology. They are about 650 words long. Columns can include a bibliography which will be available only onthe journal website.
J Psychiatry Neurosci 2014;39(1)
Off-label antipsychotic use and tardive dyskinesia
ment. Int Rev Neurobiol
a systematic review of 1-year studies.
Am J Psychiatry
schizophrenia: relationship of ‘tardive’
A, et al. Increasing off-label use of an-
nesia and new antipsychotics. Curr Opin
and negative symptoms. Br J Psychiatry
States, 1995-2008. Pharmacoepidemiol
Wade JB, Taylor MA, Kasprisin A, et al.
pairment. Biol Psychiatry
editors. Handbook of Clinical Neurology:
Hyperkinetic Movement Disorders.
medication use in Australia 2002-2007.
Aust N Z J Psychiatry
Jeste DV, Caligiuri MP, Paulsen JS, et al.
study. J Clin Psychiatry
of atypical antipsychotics: cause for con-
cern? CNS Drugs
of 266 outpatients. Arch Gen Psychiatry
hyperkinetic movement disorders. Am J
Bhidayasiri R, Fahn S, Weiner WJ, et al.
prevalence and risk factors, 1959 to 1979.
adults with antipsychotics. Arch Gen
Arch Gen Psychiatry
Crystal S, Olfson M, Huang C, et al.
dyskinesia. Int Rev Neurobiol
chotics: safety, effectiveness, and policy
Miller DD, McEvoy JP, Davis SM, et al.
Clinical correlates of tardive dyskinesia
min E supplementation? Crit Rev Food
CATIE schizophrenia trial. Schizophr Res
Caroff SN, Davis VG, Miller DD, et al.
chotics: rethinking “off-label”. Psychiatr
nia. J Clin Psychiatry
schizophrenia. Acta Psychiatr Scand
view. CNS Drugs
recognition and management. Postgrad
dyskinesia: clinical presentation and treat-
J Psychiatry Neurosci 2014;39(1)
WHO Europe evidence based recommendations on thetreatment of tobacco dependenceM Raw, P Anderson, A Batra, G Dubois, P Harrington, A Hirsch, J Le Houezec,A McNeill, D Milner, M Poetschke Langer, W Zatonski—Recommendations panel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Adrenoceptors and breast cancer: Review article Roisman R., Klemm O., Raphaeli G., and Roisman I. Dedicated to Mrs. Minka Klavins and Prof. Janis V. Klavins Albert Einstein College of Medicine, New York, NY, USA Correspondence to: Isaac Roisman, M.D., Dip. Surg., M. Surg., D.Sc. P.O.Box 45470 , Haifa 31453, Israel Tel.: (972-4)8388393, Fax: (972-4)8379503 Adrenocepto